Nabriva Therapeutics plc (NBRV) financial statements (2021 and earlier)

Company profile

Business Address 56 FITZWILLIAM SQUARE
DUBLIN, 2
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:42871028784
Cash and cash equivalents41861028733
Short-term investments000051
Other undisclosed cash, cash equivalents, and short-term investments00(0)00
Receivables01456
Inventory, net of allowances, customer advances and progress billings61   
Inventory61   
Prepaid expense61121
Contract with customer, asset  2
Other undisclosed current assets420(0)(0)
Total current assets:57911099491
Noncurrent Assets
Nontrade receivables00000
Property, plant and equipment12111
Intangible assets, net (including goodwill)00000
Intangible assets, net (excluding goodwill)00000
Deferred tax assets, net  1
Total noncurrent assets:13223
TOTAL ASSETS:58941109693
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1617181316
Accounts payable35353
Accrued liabilities131215813
Taxes payable    0
Deferred revenue1 
Debt2    
Total current liabilities:1917181316
Noncurrent Liabilities
Long-term debt and lease obligation635240 
Long-term debt, excluding current maturities635240 
Liabilities, other than long-term debt12000
Other liabilities12000
Total noncurrent liabilities:7362400
Total liabilities:2553421416
Stockholders' equity
Stockholders' equity attributable to parent, including:3341698277
Common stock011 3
Additional paid in capital579517462361279
Accumulated other comprehensive income00000
Accumulated deficit(546)(477)(394)(279)(205)
Other undisclosed stockholders' equity attributable to parent   0 
Total stockholders' equity:3341698277
TOTAL LIABILITIES AND EQUITY:58941109693

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues591056
Revenue, net56
Cost of revenue
(Cost of Goods and Services Sold)
(1)(0)   
Gross profit:491056
Operating expenses(70)(89)(124)(79)(62)
Operating loss:(66)(79)(114)(74)(55)
Nonoperating income (expense)10(0)0(1)
Investment income, nonoperating0000 
Other nonoperating income (expense)10(0) 0
Interest and debt expense(4)(4)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes    0
Loss from continuing operations before equity method investments, income taxes:(69)(83)(115)(73)(56)
Other undisclosed income from continuing operations before income taxes   0 
Loss from continuing operations before income taxes:(69)(83)(115)(73)(56)
Income tax expense (benefit)(0)(0)(0)(1)1
Net loss available to common stockholders, diluted:(69)(83)(115)(74)(55)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(69)(83)(115)(74)(55)
Other comprehensive income   0 
Comprehensive loss:(69)(83)(115)(74)(55)
Other undisclosed comprehensive income, net of tax, attributable to parent    0
Comprehensive loss, net of tax, attributable to parent:(69)(83)(115)(74)(55)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: